Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation

REFERENCES

• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575–589.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: A pilot study. J Ocul Pharmacol Ther. 2008;24(3):351–361.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581.
   PubMed Web of Science ®Google Scholar
• Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97(2):134–138.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: Results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481–486.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: A 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223–2231.
   PubMed Web of Science ®Google Scholar
• Martel JN, Esterberg E, Nagpal A, et al. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20(1):18–26.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2016;6736(VisualIi):1–10.
   Google Scholar
• Durrani K, Kempen JH, Ying G-S, et al. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. March. 2016;22:1–8.
   Google Scholar
• Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)––Humira (adalimumab) injection.
   Google Scholar
• Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behçet disease. Ocul Immunol Inflamm. 2014;22(1):27–33.
   PubMed Web of Science ®Google Scholar
• Hamam RN, Barikian AW, Antonios RS, et al. intravitreal adalimumab in active noninfectious uveitis: A pilot study. Ocul Immunol Inflamm. 2016;24(3):319–326.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: A pilot study in 15 patients. Am J Ophthalmol. 2012;154(3):534–541.e1.
   PubMed Web of Science ®Google Scholar
• Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012;28(6):628–631.
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Nussenblatt RB. International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103(2):234–235.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behçet’s disease. International study group for Behçet’s disease. Lancet (London, England). 1990;335(8697):1078–1080.
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501–507.
   PubMed Web of Science ®Google Scholar
• Myung JS, Aaker GD, Kiss S. Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol. 2010;4:1423–1426.
   PubMedGoogle Scholar
• Ghosn CR, Li Y, Orilla WC, et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(6):2917–2923.
   PubMed Web of Science ®Google Scholar
• Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117(8):1612–1616.
   PubMed Web of Science ®Google Scholar
• Hay H, Cohen J. Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. J Clin Lab Immunol. 1989;29(3):151–155.
   PubMedGoogle Scholar
• Humphreys DT, Wilson MR. Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents. Cytokine. 1999;11(10):773–782.
   PubMed Web of Science ®Google Scholar
• Hehner SP, Hofmann TG, Ratter F, et al. Tumor necrosis factor-alpha-induced cell killing and activation of transcription factor NF-kappaB are uncoupled in L929 cells. J Biol Chem. 1998;273(29):18117–18121.
   PubMed Web of Science ®Google Scholar
• Teng Z, Kuang X, Wang J, et al. Real-time cell analysis––a new method for dynamic, quantitative measurement of infectious viruses and antiserum neutralizing activity. J Virol Methods. 2013;193(2):364–370.
   PubMed Web of Science ®Google Scholar